Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levocarnitine + methylphenidate is a combination of two agents, each with distinct mechanisms and indications. Levocarnitine (L-carnitine) is a naturally occurring amino acid derivative involved in the transport of long-chain fatty acids into mitochondria for energy production, primarily used to treat carnitine deficiency[4][7]. Methylphenidate is a central nervous system stimulant that blocks the reuptake of dopamine and norepinephrine, enhancing neurotransmission in the brain; it is widely used for attention deficit hyperactivity disorder (ADHD) and narcolepsy[6]. The combination has been studied as an adjunctive therapy for ADHD, but clinical trials have not demonstrated significant additional benefit over methylphenidate alone[1][2][5][8]. Both drugs are available as generics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levocarnitine + methylphenidate.